Chapter 020

Opioid Analgesics and Antagonists

Michael H. Ossipov, Gerald F. Gebhart, and Frank Porreca

CITED REFERENCES

  1. Barkin RL, Barkin SJ, Barkin DS: Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther 13:534-542, 2006.PUBMED Abstract
  2. Borison HL: Central nervous system respiratory depressants-narcotic analgesics. Pharmacol Ther [B] 3:227-237, 1977.PUBMED Abstract
  3. Bovill JG, Sebel PS, Stanley TH: Opioid analgesics in anesthesia: with special reference to their use in cardiovascular anesthesia. Anesthesiology 61:731-755, 1984.
  4. Donner B, Zenz M, Strumpf M, et al: Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15:168-175, 1998.PUBMED Abstract
  5. Fantin M, Fischetti C, Trapella C, et al: Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways. Br J Pharmacol 152:549-555, 2007.PUBMED Abstract
  6. Fields H: State-dependent opioid control of pain. Nat Rev Neurosci 5:565-575, 2004.PUBMED Abstract
  7. Gavériaux-Ruff C, Peluso J, Befort K, et al: Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the δ- and κ-opioid receptors. Mol Brain Res 48:298-304, 1997.PUBMED Abstract
  8. Gebhart GF, Proudfit HK: Descending modulation of pain processing. In Hunt S, Koltzenburg M, editors: The neurobiology of pain, Oxford, 2004, Oxford University Press.
  9. Grace D, Fee JP: A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg 83:1055-1059, 1996.PUBMED Abstract
  10. Grond S, Zech D, Lehman KA, et al: Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69:191-198, 1997.PUBMED Abstract
  11. Hosobuchi Y, Adams JE, Linchitz R: Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 197:183-186, 1977.PUBMED Abstract
  12. Houde RW, Wallenstein SL, Beaver WT: Clinical measurement of pain. In de Stevens G, editor: Analgetics, New York, 1965, Academic Press.
  13. Hughes J: Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 88:295-308, 1975.PUBMED Abstract
  14. Kaiko RF, Wallenstein SL, Rogers AG, et al: Narcotics in the elderly. Med Clin North Am 66:1079-1089, 1982.PUBMED Abstract
  15. Kieffer BL: Molecular aspects of opioid receptors. In Dickenson AH, Besson J-MR, editors: The pharmacology of pain. Handbook of experimental pharmacology, vol 130, Berlin, 1997, Springer.
  16. Laulin JP, Celerier E, Larcher A, et al: Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 89:631-636, 1999.PUBMED Abstract
  17. Loder E: Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalalgia 26:89-97, 2006.PUBMED Abstract
  18. Mannelli P, Peindl K, Masand PS, et al: Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother 7:1265-1277, 2007.PUBMED Abstract
  19. Marcus MME, Gogarten W, Van Aken H: Opioids in obstetrics. In Stein C, editor: Opioids in pain control, Cambridge, 1999, Cambridge University Press.
  20. Martini L, Whistler JL: The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17:556-564, 2007.PUBMED Abstract
  21. Meunier JC, Mollereau C, Toll L, et al: Isolation and structure of the endogenous agonist of opioid receptor-like ORL-1 receptor. Nature 377:532-535, 1995.PUBMED Abstract
  22. Miller RJ: Peptides as neurotransmitters: focus on the enkephalins and endorphins. Pharmacol Ther 12:73-108, 1981.PUBMED Abstract
  23. Miller RR, Feingold A, Paxinos J: Propoxyphene hydrochloride: a critical review. JAMA 213:996-1006, 1970.PUBMED Abstract
  24. Mogensen T, Eliasen K, Ejlersen E, et al: Epidural clonidine enhances postoperative analgesia from a combined low-dose epidural bupivacaine and morphine regimen. Anesth Analg 75:607-610, 1992.PUBMED Abstract
  25. Moore PA: JADA Continuing Education: pain management in dental practice: tramadol vs. codeine combinations. J Am Dent Assoc 130:1075-1079, 1999.PUBMED Abstract
  26. Okuda-Ashitaka E, Ito S: Nocistatin: a novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor. Peptides 21:1101-1109, 2000.PUBMED Abstract
  27. Ossipov MH, Lai J, King T, et al: Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80:319-324, 2005.PUBMED Abstract
  28. Owen JA, Sitar DS, Berger L, et al: Age-related morphine kinetics. Clin Pharmacol Ther 34:364-368, 1983.PUBMED Abstract
  29. Portenoy RK: Tolerance to opioid analgesics: clinical aspects. Cancer Surv 21:49-65, 1994.PUBMED Abstract
  30. Portenoy RK, Thaler HT, Inturrisi CE, et al: The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 51:422-431, 1992.PUBMED Abstract
  31. Price DD: Psychological mechanisms of pain and analgesia. Progress in pain research and management, vol 15, Seattle, 1999, IASP Press.
  32. Raynor K, Kong H, Chen Y, et al: Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45:330-334, 1994.PUBMED Abstract
  33. Reinscheid RK, Nothacker HP, Bourson A, et al: Orophanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270:792-794, 1995.PUBMED Abstract
  34. Salmanzadeh F, Fathollahi Y, Semnanian S, et al: Dependence on morphine impairs the induction of long-term potentiation in the CA1 region of rat hippocampal slices. Brain Res 965:108-113, 2003.
  35. Sapira JD: Speculations concerning opium abuse and world history. Perspect Biol Med 18:379-398, 1975.PUBMED Abstract
  36. Scott LJ, Perry CM: Tramadol: a review of its use in perioperative pain. Drugs 60:139-176, 2000.PUBMED Abstract
  37. Simon EJ: The opiate receptors. Neurochem Res 1:3-28, 1976.PUBMED Abstract
  38. Stein C, Cabot PJ, Schafer M: Peripheral opioid analgesia: mechanisms and clinical implications. In Stein C, editor: Opioids in pain control, Cambridge, 1999, Cambridge University Press.
  39. Sternini C, Spann M, Anton B, et al: Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A 93:9241-9246, 1996.PUBMED Abstract
  40. Tambour S, Quertemont E: Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 21:9-28, 2007.PUBMED Abstract
  41. Thorn SE, Wattwil M, Lindberg G, et al: Systemic and central effects of morphine on gastroduodenal motility. Acta Anesthesiol Scand 40:177-186, 1996.PUBMED Abstract
  42. Twycross RG: Opioids. In Wall PD, Melzack R, editors: Textbook of pain, London, 1999, Churchill Livingstone.
  43. Tzschentke TM, Christoph T, Kogel B, et al: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323:265-276, 2007.
  44. Woody GE, Senay EC, Geller A, et al: An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend 72:163-168, 2003.
  45. Wynn RL: Non-traditional analgesics for dental pain. Gen Dent 56:122-124, 2008.PUBMED Abstract
  46. Yaksh TL: The spinal actions of opioids. In Hertz A, editor: Opioids II. Handbook of experimental pharmacology, vol 104, Berlin, 1993, Springer-Verlag.
  47. Zadina JE, Hackler L, Ge L, et al: A potent and selective endogenous agonist for the m-opiate receptor. Nature 386:499-502, 1997.PUBMED Abstract
  48. Zadina JE, Martin-Schild S, Gerall AA, et al: Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density. Ann N Y Acad Sci 897:136-144, 1999.PUBMED Abstract
  49. Zeilhofer HU, Reinscheid RK, Okuda-Ashitaka E: Nociceptin, nocistatin and pain. In Dostrovsky JO, Carr DB, Koltzenburg M, editors: Proceedings of the 10th World Congress on Pain. Progress in pain research and management, vol 24, Seattle, 2003, IASP Press.

GENERAL REFERENCES

  1. Dickenson AH, Besson J-MR, editors: The pharmacology of pain. Handbook of experimental pharmacology, vol 130, Berlin, 1997, Springer.
  2. Dostrovsky J, Carr DB, Koltzenburg M, editors: Proceedings of the 10th World Congress on Pain, Seattle, 2003, IASP Press.
  3. Peptides 21:891-1154, 2000. (issue devoted to nociceptin/orphanin FQ/ORL-1 receptor system)
  4. Reisine T: Opiate receptors, Neuropharmacology 34:463-472, 1995.
  5. Stein C, editor: Opioids in pain control, Cambridge, 1999, Cambridge University Press.
  6. Taylor DA, Fleming WA: Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids, J Pharmacol Exp Ther 297:11-18, 2001.PUBMED Abstract
  7. Williams JT, Christie MJ, Manzoni O: Cellular and synaptic adaptations mediating opioid dependence, Physiol Rev 81:299-343, 2001.
  8. Zakrezewska JM, Harrison SD, editors: Assessment and management of orofacial pain. Pain research and clinical management, vol 14, Amsterdam, 2002, Elsevier.